MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Kodu・Aktsiate loetelu・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Suletud

17.49 -1.19

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.39

Max

17.65

Põhinäitajad
By Trading Economics
Sissetulek	35M 9.5M
Müük	35M 94M
Kasumimarginaal	10.158
Töötajad	619
EBITDA	35M 17M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+15.58% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	147M 2.8B
Eelmine avamishind	18.68
Eelmine sulgemishind	17.49

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

8.81 / 10.18 Toetus ja vastupanu

Adaptive Biotechnologies Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. jaan 2026, 23:29 UTC

Kuumad aktsiad

Stocks to Watch: Atossa Therapeutics, Union Pacific

18. jaan 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Standalone Plan Offers Clear Path to Valuation of More Than Y40,000 a Share by 2028

18. jaan 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Opposing Toyota Fudosan's Revised Tender Offer for Toyota Industries

18. jaan 2026, 23:55 UTC

Market Talk

Oil Falls as Middle East Tensions Continue to Fade -- Market Talk

18. jaan 2026, 23:40 UTC

Market Talk

Precious Metals Climb After Trump Threatens Europe With Tariffs Over Greenland -- Market Talk

18. jaan 2026, 22:29 UTC

Market Talk

Miners Seen Extending Rally as Generalist Investors Warm to Sector -- Market Talk

18. jaan 2026, 21:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. jaan 2026, 21:03 UTC

Market Talk

More Australian Voters Switch Away From Major Parties -- Market Talk

18. jaan 2026, 19:46 UTC

Market Talk

FX Markets Taking Latest Trump Tariff Threat Calmly -- Market Talk

17. jaan 2026, 15:06 UTC

Omandamised, ülevõtmised, äriostud

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17. jaan 2026, 03:10 UTC

Omandamised, ülevõtmised, äriostud

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16. jaan 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16. jaan 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16. jaan 2026, 21:48 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16. jaan 2026, 21:41 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16. jaan 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16. jaan 2026, 20:44 UTC

Tulu

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16. jaan 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16. jaan 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16. jaan 2026, 19:12 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Adaptive Biotechnologies Corp Prognoos

Hinnasiht

By TipRanks

15.58% tõus

12 kuu keskmine prognoos

Keskmine 20.25 USD 15.58%

Kõrge 21 USD

Madal 20 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Adaptive Biotechnologies Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Adaptive Biotechnologies Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

8.81 / 10.18Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.